Cargando…

Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope

BACKGROUND: Vasovagal syncope is a common cause of syncope which, if recurrent, can have multiple negative consequences such as injury and occupational disability. Various medications can be used to decrease the recurrence of vasovagal syncope but there are no drugs that can be used by patients to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutson, Paul, Guieu, Regis, Deharo, Jean-Claude, Michelet, Pierre, Brignole, Michele, Vander Ark, Cassondra, Hamdan, Mohamed H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885938/
https://www.ncbi.nlm.nih.gov/pubmed/35150431
http://dx.doi.org/10.1007/s40268-021-00378-9
_version_ 1784660544966361088
author Hutson, Paul
Guieu, Regis
Deharo, Jean-Claude
Michelet, Pierre
Brignole, Michele
Vander Ark, Cassondra
Hamdan, Mohamed H.
author_facet Hutson, Paul
Guieu, Regis
Deharo, Jean-Claude
Michelet, Pierre
Brignole, Michele
Vander Ark, Cassondra
Hamdan, Mohamed H.
author_sort Hutson, Paul
collection PubMed
description BACKGROUND: Vasovagal syncope is a common cause of syncope which, if recurrent, can have multiple negative consequences such as injury and occupational disability. Various medications can be used to decrease the recurrence of vasovagal syncope but there are no drugs that can be used by patients to interrupt a perceived vasovagal episode. METHODS: A phase I study was performed to evaluate the tolerability and safety of a gel formulation containing capsaicin (1 mg), phenylephrine HCL (PE) and caffeine citrate (200 mg) (CPC) in normal adult volunteers. Secondary objectives were to characterize the pharmacokinetics (PK) of the CPC formulation and the highest dose of PE needed to achieve a target increase in systolic BP of at least 40 mmHg. After receiving the first dose, a second dose of the CPC mixture was administered at 2 h. Suboptimal changes in systolic blood pressure (SBP) were noted at PE doses of 0.6, 1.2, and 1.8 mg, therefore a second cohort was studied at PE doses of 10, 20, and 30 mg. Blood samples were collected in rapid sequence and were assayed for all three drugs. RESULTS: A total of 17 subjects received the drug with no serious adverse effects reported. All doses were well tolerated, although the capsaicin content usually caused expected temporary oral and gastric discomfort. One subject did not complete the study because of a vasovagal reaction that was associated with the frequent blood sampling. There was a 5–25 min lag in the appearance of measurable blood concentrations of capsaicin and phenylephrine. Most subjects had baseline caffeine concentrations from dietary use, with a gradual increase noted after 15 min consistent with GI absorption. Although the intended criterion of a 40 mmHg increase in SBP was not reached, a clinically significant increase in BP for at least 15 min was noted in the six subjects who received the highest dose of PE (30 mg), with a gradual decline over the next 2 h. CONCLUSION: The ternary mixture of capsaicin, phenylephrine, and caffeine was well tolerated when administered as two sublingual/oral doses over a 2-h period.
format Online
Article
Text
id pubmed-8885938
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88859382022-03-08 Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope Hutson, Paul Guieu, Regis Deharo, Jean-Claude Michelet, Pierre Brignole, Michele Vander Ark, Cassondra Hamdan, Mohamed H. Drugs R D Original Research Article BACKGROUND: Vasovagal syncope is a common cause of syncope which, if recurrent, can have multiple negative consequences such as injury and occupational disability. Various medications can be used to decrease the recurrence of vasovagal syncope but there are no drugs that can be used by patients to interrupt a perceived vasovagal episode. METHODS: A phase I study was performed to evaluate the tolerability and safety of a gel formulation containing capsaicin (1 mg), phenylephrine HCL (PE) and caffeine citrate (200 mg) (CPC) in normal adult volunteers. Secondary objectives were to characterize the pharmacokinetics (PK) of the CPC formulation and the highest dose of PE needed to achieve a target increase in systolic BP of at least 40 mmHg. After receiving the first dose, a second dose of the CPC mixture was administered at 2 h. Suboptimal changes in systolic blood pressure (SBP) were noted at PE doses of 0.6, 1.2, and 1.8 mg, therefore a second cohort was studied at PE doses of 10, 20, and 30 mg. Blood samples were collected in rapid sequence and were assayed for all three drugs. RESULTS: A total of 17 subjects received the drug with no serious adverse effects reported. All doses were well tolerated, although the capsaicin content usually caused expected temporary oral and gastric discomfort. One subject did not complete the study because of a vasovagal reaction that was associated with the frequent blood sampling. There was a 5–25 min lag in the appearance of measurable blood concentrations of capsaicin and phenylephrine. Most subjects had baseline caffeine concentrations from dietary use, with a gradual increase noted after 15 min consistent with GI absorption. Although the intended criterion of a 40 mmHg increase in SBP was not reached, a clinically significant increase in BP for at least 15 min was noted in the six subjects who received the highest dose of PE (30 mg), with a gradual decline over the next 2 h. CONCLUSION: The ternary mixture of capsaicin, phenylephrine, and caffeine was well tolerated when administered as two sublingual/oral doses over a 2-h period. Springer International Publishing 2022-02-12 2022-03 /pmc/articles/PMC8885938/ /pubmed/35150431 http://dx.doi.org/10.1007/s40268-021-00378-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Hutson, Paul
Guieu, Regis
Deharo, Jean-Claude
Michelet, Pierre
Brignole, Michele
Vander Ark, Cassondra
Hamdan, Mohamed H.
Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope
title Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope
title_full Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope
title_fullStr Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope
title_full_unstemmed Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope
title_short Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope
title_sort safety, pharmacokinetic, and pharmacodynamic study of a sublingual formula for the treatment of vasovagal syncope
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885938/
https://www.ncbi.nlm.nih.gov/pubmed/35150431
http://dx.doi.org/10.1007/s40268-021-00378-9
work_keys_str_mv AT hutsonpaul safetypharmacokineticandpharmacodynamicstudyofasublingualformulaforthetreatmentofvasovagalsyncope
AT guieuregis safetypharmacokineticandpharmacodynamicstudyofasublingualformulaforthetreatmentofvasovagalsyncope
AT deharojeanclaude safetypharmacokineticandpharmacodynamicstudyofasublingualformulaforthetreatmentofvasovagalsyncope
AT micheletpierre safetypharmacokineticandpharmacodynamicstudyofasublingualformulaforthetreatmentofvasovagalsyncope
AT brignolemichele safetypharmacokineticandpharmacodynamicstudyofasublingualformulaforthetreatmentofvasovagalsyncope
AT vanderarkcassondra safetypharmacokineticandpharmacodynamicstudyofasublingualformulaforthetreatmentofvasovagalsyncope
AT hamdanmohamedh safetypharmacokineticandpharmacodynamicstudyofasublingualformulaforthetreatmentofvasovagalsyncope